Pelage Pharmaceuticals Announces $16.75M Series A Financing to Advance Hair Loss Treatment
Pelage Pharmaceuticals has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures to advance a first-in-class treatment for androgenetic alopecia and other types of alopecia including chemotherapy-induced hair loss. PP405 is designed to inhibit the mitochondrial pyruvate carrier (MPC) to specifically reactivate the dormant […]